DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth is attractive because it combines connected FDA-cleared devices, proprietary data, and AI-driven coaching into a vertically integrated chronic-care platform that can sustain engagement and improve clinical outcomes better than software-only peers. The company is showing tangible commercial traction, including a $13 million contracted ARR base, a pipeline of $127 million across 2026 opportunities, expanded access to 116 million covered lives, and new wins that could lift recurring revenue and triple revenue from a top-5 national health plan relationship. Its 1Q26 results also showed improving fundamentals, with 80%+ gross margins in B2B2C for a ninth consecutive quarter, non-GAAP operating expenses down 17% year over year, and a credible path toward cash-flow breakeven by end of 2027.

DarioHealth is facing a soft demand backdrop, as 2Q revenue of $5.2M missed estimates and weakness in both B2C and B2B offset its 65% gross margin and improved cost discipline. Despite $13M in new contracted ARR and management’s aim to shrink adjusted operating loss by 30% in 2026 and reach cash-flow breakeven by mid 2027, growth visibility remains limited in B2B2C and strategic partnerships, with churn and customer retention still key risks. The company’s repeated reliance on dilutive capital raises, alongside a challenging digital health market and possible constrained investment, suggests fundamental pressure on revenue growth, cash runway, and long-term shareholder value.